|

Mervometostat (PF-06821497) Clinical Trials

1 actively recruiting trial across 1 location

Also known as: EZH2i

Pipeline

Phase 1: 1

Top Sponsors

  • Pfizer1

Indications

  • Metastatic Castration-resistant Prostate Cancer, mCRPC1
  • Follicular Lymphoma ( FL)1
  • Small Cell Lung Cancer (SCLC)1
  • Lung Cancer1
  • Cancer1

Tucson, Arizona1 trial

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Banner-University Medical Center Tucson

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.